Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Katzenstein, DA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 56 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Shulman, NS; Machekano, RA; Shafer, RW; Winters, MA; Zolopa, AR; Liou, SH; Hughes, M; Katzenstein, DA
      Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    2. Katzenstein, DA; Hughes, MD; Albrecht, M; Liou, SH; Murphy, R; Balfour, H; Para, M; Hammer, S
      Virologic and CD4 cell response to zidovudine or zidovudine and lamivudinefollowing didanosine treatment of human immunodeficiency virus infection

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    3. Albrecht, MA; Bosch, RJ; Hammer, SM; Liou, SH; Kessler, H; Para, MF; Eron, J; Valdez, H; Dehlinger, M; Katzenstein, DA
      Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

      NEW ENGLAND JOURNAL OF MEDICINE
    4. Lathey, JL; Tierney, C; Chang, SYP; D'Aquila, RT; Bettendorf, DM; Alexander, HC; Santini, CD; Hughes, AM; Barroga, CF; Spector, SA; Landes, JE; Hammer, SM; Katzenstein, DA
      Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy

      JOURNAL OF INFECTIOUS DISEASES
    5. Currier, JS; Spino, C; Grimes, J; Wofsy, CB; Katzenstein, DA; Hughes, MD; Hammer, SM; Cotton, DJ
      Differences between women and men in adverse events and CD4(+) responses to nucleoside analogue therapy for HIV infection

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    6. Shulman, NS; Zolopa, AR; Passaro, DJ; Murlidharan, U; Israelski, DM; Brosgart, CL; Miller, MD; Van Doren, S; Shafer, RW; Katzenstein, DA
      Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    7. Machekano, RN; Bassett, MT; Zhou, PS; Mbizvo, MT; Latif, AS; Katzenstein, DA
      Report of sexually transmitted diseases by HIV infected men during follow up: time to target the HIV infected?

      SEXUALLY TRANSMITTED INFECTIONS
    8. Kim, S; Hughes, MD; Hammer, SM; Jackson, JB; DeGruttola, V; Katzenstein, DA
      Both serum HIV type 1 RNA levels and CD4(+) lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4(+) cells per cubic millimeter

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    9. Albrecht, MA; Hughes, MD; Liou, SH; Katzenstein, DA; Murphy, R; Balfour, HH; Para, MF; Valdez, H; Hammer, SM
      Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    10. Katzenstein, DA; Hughes, M; Albrecht, M; Hammer, S; Para, M; Murphy, R; Valdez, H; Haubrich, R; Liou, S
      Virologic and CD4(+) cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    11. Batra, M; Tien, PC; Shafer, RW; Contag, CH; Katzenstein, DA
      HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    12. Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Vella, S; Yeni, PG; Volberding, PA
      Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    13. Katzenstein, DA; Kundu, S; Spritzler, J; Smoller, BR; Haszlett, P; Valentine, F; Merigan, TC
      Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    14. Tien, PC; Chiu, T; Latif, A; Ray, S; Batra, M; Contag, CH; Zejena, L; Mbizvo, M; Delwart, EL; Mullins, JI; Katzenstein, DA
      Primary subtype C HIV-1 infection in Harare, Zimbabwe

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
    15. Gwanzura, L; Latif, A; Bassett, M; Machekano, R; Katzenstein, DA; Mason, PR
      Syphilis serology and HIV infection in Harare, Zimbabwe

      SEXUALLY TRANSMITTED INFECTIONS
    16. Katzenstein, DA
      Hot papers - AIDS - A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 percubic millimeter by S.M. Hammer, D.A. Katzenstein, M.D. Hughes, H. Gundacker, R.T. Schooley, R.H. Haubrich, W.K. Henry, M.M. Lederman, J.P. Phair, M.Niu, M.S. Hirsch, T.C. Merigan - Comments

      SCIENTIST
    17. Min, J; Katzenstein, DA
      Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: Association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    18. Shafer, RW; Chuang, TK; Hsu, P; White, CB; Katzenstein, DA
      Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    19. Brambilla, D; Reichelderfer, PS; Bremer, JW; Shapiro, DE; Hershow, RC; Katzenstein, DA; Hammer, SM; Jackson, B; Collier, AC; Sperling, RS; Fowler, MG; Coombs, RW
      The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements

      AIDS
    20. Katzenstein, DA; Mbizvo, M; Zijenah, L; Gittens, T; Munjoma, M; Hill, D; Madzime, S; Maldonado, Y
      Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe

      JOURNAL OF INFECTIOUS DISEASES
    21. ROESEL DJ; GWANZURA L; MASON PR; JOFFE M; KATZENSTEIN DA
      POLYMERASE-CHAIN-REACTION DETECTION OF HAEMOPHILUS-DUCREYI DNA

      SEXUALLY TRANSMITTED INFECTIONS
    22. OLSON JE; ZOLOPA AR; KATZENSTEIN DA
      PROTEASE INHIBITOR THERAPY, HIV-1 RNA, AND CD4-CELL RESPONSE IN A CLINICAL-PRACTICE( T)

      Journal of investigative medicine
    23. REY D; HUGHES M; PI JT; WINTERS M; MERIGAN TC; KATZENSTEIN DA
      HIV-1 REVERSE-TRANSCRIPTASE CODON-215 MUTATION IN PLASMA RNA - IMMUNOLOGICAL AND VIROLOGICAL RESPONSES TO ZIDOVUDINE

      Journal of acquired immune deficiency syndromes and human retrovirology
    24. MASON PR; GWANZURA L; LATIF AS; MAROWA E; RAY S; KATZENSTEIN DA
      ANTIMICROBIAL RESISTANCE IN GONOCOCCI ISOLATED FROM PATIENTS AND FROMCOMMERCIAL SEX WORKERS IN HARARE, ZIMBABWE

      International journal of antimicrobial agents
    25. GREGSON S; MACHEKANO R; DONNELLY CA; MBIZVO MT; ANDERSON RM; KATZENSTEIN DA
      ESTIMATING HIV INCIDENCE FROM AGE-SPECIFIC PREVALENCE DATA - COMPARISON WITH CONCURRENT COHORT ESTIMATES IN A STUDY OF MALE FACTORY-WORKERS, HARARE, ZIMBABWE

      AIDS
    26. Simpson, DM; Katzenstein, DA; Hughes, MD; Hammer, SM; Williamson, DL; Jiang, Q; Pi, JT
      Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial

      AIDS
    27. CARPENTER CCJ; FISCHL MA; HAMMER SM; HIRSCH MS; JACOBSEN DM; KATZENSTEIN DA; MONTANER JSG; RICHMAN DD; SAAG MS; SCHOOLEY RT; THOMPSON MA; VELLA S; YENI PG; VOLBERDING PA
      ANTIRETROVIRAL THERAPY FOR HIV-INFECTION IN 1998 - UPDATED RECOMMENDATIONS OF THE INTERNATIONAL AIDS SOCIETY USA PANEL

      JAMA, the journal of the American Medical Association
    28. LATHEY JL; HUGHES MD; FISCUS SA; PI T; JACKSON JB; RASHEED S; ELBEIK T; REICHMAN R; JAPOUR A; DAQUILA RT; SCOTT W; GRIFFITH BP; HAMMER SM; KATZENSTEIN DA
      VARIABILITY AND PROGNOSTIC VALUES OF VIROLOGICAL AND CD4 CELL MEASURES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-INFECTED PATIENTS WITH 200-500 CD4 CELLS MM(3) (ACTG-175)/

      The Journal of infectious diseases
    29. FISCUS SA; HUGHES MD; LATHEY JL; PI T; JACKSON JB; RASHEED S; ELBEIK T; REICHMAN R; JAPOUR A; BYINGTON R; SCOTT W; GRIFFITH BP; KATZENSTEIN DA; HAMMER SM
      CHANGES IN VIROLOGICAL MARKERS AS PREDICTORS OF CD4 CELL DECLINE AND PROGRESSION OF DISEASE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTEDADULTS TREATED WITH NUCLEOSIDES

      The Journal of infectious diseases
    30. MARSCHNER IC; COLLIER AC; COOMBS RW; DAQUILA RT; DEGRUTTOLA V; FISCHL MA; HAMMER SM; HUGHES MD; JOHNSON VA; KATZENSTEIN DA; RICHMAN DD; SMEATON LM; SPECTOR SA; SAAG MS
      USE OF CHANGES IN PLASMA-LEVELS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA TO ASSESS THE CLINICAL BENEFIT OF ANTIRETROVIRAL THERAPY

      The Journal of infectious diseases
    31. WINTERS MA; COOLLEY KL; GIRARD YA; LEVEE DJ; HAMDAN H; SHAFER RW; KATZENSTEIN DA; MERIGAN TC
      A 6-BASEPAIR INSERT IN THE REVERSE-TRANSCRIPTASE GENE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CONFERS RESISTANCE TO MULTIPLE NUCLEOSIDE INHIBITORS

      The Journal of clinical investigation
    32. RAY CS; MASON PR; SMITH H; ROGERS L; TOBAIWA O; KATZENSTEIN DA
      AN EVALUATION OF DIPSTICK-DOT IMMUNOASSAY IN THE DETECTION OF ANTIBODIES TO HIV-I AND HIV-2 IN ZIMBABWE

      TM & IH. Tropical medicine & international health
    33. CARPENTER CCJ; FISCHL MA; HAMMER SM; HIRSCH MS; JACOBSEN DM; KATZENSTEIN DA; MONTANER JSG; RICHMAN DD; SAAG MS; SCHOOLEY RT; THOMPSON MA; VELLA S; YENI PG; VOLBERDING PA
      ANTIRETROVIRAL THERAPY FOR HIV-INFECTION IN 1997 - UPDATED RECOMMENDATIONS OF THE INTERNATIONAL-AIDS-SOCIETY USA PANEL

      JAMA, the journal of the American Medical Association
    34. KATZENSTEIN DA
      ANTIRETROVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN 1997

      Western journal of medicine
    35. KATZENSTEIN DA
      THE RELATION OF VIROLOGICAL AND IMMUNOLOGICAL MARKERS TO CLINICAL OUTCOMES AFTER NUCLEOSIDE THERAPY IN HIV-AFFECTED ADULTS WITH 200 TO 500 CD4 CELLS PER CUBIC MILLIMETER (VOL 335, PG 1091, 1996)

      The New England journal of medicine
    36. SIMPSON DM; KATZENSTEIN DA; HAMMER SM; HUGHES MD; WILIAMSON D; JIANG Q; PI JT
      NEUROMUSCULAR FUNCTION IN HIV-INFECTION - ANALYSIS OF A PLACEBO-CONTROLLED COMBINATION ANTIRETROVIRAL TRIAL

      Neurology
    37. SHAFER RW; EISEN JA; MERIGAN TC; KATZENSTEIN DA
      SEQUENCE AND DRUG SUSCEPTIBILITY OF SUBTYPE-C REVERSE-TRANSCRIPTASE FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROCONVERTERS IN ZIMBABWE

      Journal of virology
    38. MONTANO MA; NOVITSKY VA; BLACKARD JT; CHO NL; KATZENSTEIN DA; ESSEX M
      DIVERGENT TRANSCRIPTIONAL REGULATION AMONG EXPANDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SUBTYPES

      Journal of virology
    39. BASSETT MT; MCFARLAND WC; RAY S; MBIZVO MT; MACHEKANO R; VANDEWIJGERT JHHM; KATZENSTEIN DA
      RISK-FACTORS FOR HIV-INFECTION AT ENROLLMENT IN AN URBAN MALE FACTORYCOHORT IN HARARE, ZIMBABWE

      Journal of acquired immune deficiency syndromes and human retrovirology
    40. MASON PR; GWANZURA L; LATIF AS; RAY S; VANDEWIJGERT J; KATZENSTEIN DA
      ANTIMICROBIAL SUSCEPTIBILITY PATTERNS AMONGST GROUP-B STREPTOCOCCI FROM WOMEN IN HARARE, ZIMBABWE

      International journal of antimicrobial agents
    41. CARPENTER CCJ; FISCHL MA; HAMMER SM; HIRSCH MS; JACOBSEN DM; KATZENSTEIN DA; MONTANER JSG; RICHMAN DD; SAAG MS; SCHOOLEY RT; THOMPSON MA; VELLA S; YENI PG; VOLBERDING PA
      ANTIRETROVIRAL THERAPY FOR HIV-INFECTION IN 1996 - RECOMMENDATIONS OFAN INTERNATIONAL PANEL

      JAMA, the journal of the American Medical Association
    42. HAMMER SM; KATZENSTEIN DA; HUGHES MD; GUNDACKER H; SCHOOLEY RT; HAUBRICH RH; HENRY WK; LEDERMAN MM; PHAIR JP; NIU M; HIRSCH MS; MERIGAN TC; BLASCHKE TF; SIMPSON D; MCLAREN C; ROONEY J; SALGO M
      A TRIAL COMPARING NUCLEOSIDE MONOTHERAPY WITH COMBINATION THERAPY IN HIV-INFECTED ADULTS WITH CD4 CELL COUNTS FROM 200 TO 500 PER CUBIC MILLIMETER

      The New England journal of medicine
    43. KATZENSTEIN DA; HAMMER SM; HUGHES MD; GUNDACKER H; JACKSON JB; FISCUS S; RASHEED S; ELBEIK T; REICHMAN R; JAPOUR A; MERIGAN TC; HIRSCH MS
      THE RELATION OF VIROLOGICAL AND IMMUNOLOGICAL MARKERS TO CLINICAL OUTCOMES AFTER NUCLEOSIDE THERAPY IN HIV-INFECTED ADULTS WITH 200 TO 500 CD4 CELLS PER CUBIC MILLIMETER

      The New England journal of medicine
    44. RAMACHANDRAN R; KATZENSTEIN DA; WINTERS MA; KUNDU SK; MERIGAN TC
      POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 AND THYMOSIN ALPHA(1) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

      The Journal of infectious diseases
    45. MCFARLAND W; KAHN JG; KATZENSTEIN DA; MVERE D; SHAMU R
      DEFERRAL OF BLOOD-DONORS WITH RISK-FACTORS FOR HIV-INFECTION SAVES LIVES AND MONEY IN ZIMBABWE

      Journal of acquired immune deficiency syndromes and human retrovirology
    46. KOZAL MJ; SHAFER RW; WINTERS MA; KATZENSTEIN DA; HALPERN J; MERIGAN TC
      THE ASSOCIATION BETWEEN HIV PHENOTYPE, VIRUS BURDEN, CODON-215 MUTATION AND CD4 CELL DECLINE - REPLY

      Journal of acquired immune deficiency syndromes and human retrovirology
    47. KATZENSTEIN DA
      VIRAL PHENOTYPE AND GENOTYPE AS MARKERS IN CLINICAL-TRIALS

      Journal of acquired immune deficiency syndromes and human retrovirology
    48. SHAFER RW; IVERSEN AKN; WINTERS MA; AGUINIGA E; KATZENSTEIN DA; MERIGAN TC
      DRUG-RESISTANCE AND HETEROGENEOUS LONG-TERM VIROLOGICAL RESPONSES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED SUBJECTS TO ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY

      The Journal of infectious diseases
    49. KOZAL MJ; SHAFER RW; WINTERS MA; KATZENSTEIN DA; MERIGAN TC
      CLARIFICATION OF A METHOD TO REVERSE TRANSCRIBE HUMAN-IMMUNODEFICIENCY-VIRUS RNA

      The Journal of infectious diseases
    50. FISCUS SA; DEGRUTTOLA V; GUPTA P; KATZENSTEIN DA; MEYER WA; LOFARO ML; KATZMAN M; RAGNI MV; REICHELDERFER PS; COOMBS RW
      IMMUNODEFICIENCY VIRUS TYPE-1 QUANTITATIVE CELL MICROCULTURE AS A MEASURE OF ANTIVIRAL EFFICACY IN A MULTICENTER CLINICAL

      The Journal of infectious diseases
    51. KOZAL MJ; SHAFER RW; WINTERS MA; KATZENSTEIN DA; AGUINIGA E; HALPERN J; MERIGAN TC
      HIV-1 SYNCYTIUM-INDUCING PHENOTYPE, VIRUS BURDEN CODON-215 REVERSE-TRANSCRIPTASE MUTATION AND CD4 CELL DECLINE IN ZIDOVUDINE-TREATED PATIENTS

      Journal of acquired immune deficiency syndromes
    52. RAMACHANDRAN RV; KATZENSTEIN DA; WOOD R; BATTS DH; MERIGAN TC
      FAILURE OF SHORT-TERM CD4-PE40 INFUSIONS TO REDUCE VIRUS LOAD IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS

      The Journal of infectious diseases
    53. SHAFER RW; KOZAL MJ; WINTERS MA; IVERSEN AKN; KATZENSTEIN DA; RAGNI MV; MEYER WA; GUPTA P; RASHEED S; COOMBS R; KATZMAN M; FISCUS S; MERIGAN TC
      COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE SELECTS FOR DRUG-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS WITH UNIQUE PATTERNS OF POL GENE-MUTATIONS

      The Journal of infectious diseases
    54. KATZENSTEIN DA; WINTERS M; BUBP J; ISRAELSKI D; WINGER E; MERIGAN TC
      QUANTITATION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY CULTURE AND POLYMERASE CHAIN-REACTION IN RESPONSE TO DIDANOSINE AFTER LONG-TERM THERAPY WITH ZIDOVUDINE

      The Journal of infectious diseases
    55. KOZAL MJ; KROODSMA K; WINTERS MA; SHAFER RW; EFRON B; KATZENSTEIN DA; MERIGAN TC
      DIDANOSINE RESISTANCE IN HIV-INFECTED PATIENTS SWITCHED FROM ZIDOVUDINE TO DIDANOSINE MONOTHERAPY

      Annals of internal medicine
    56. WINTERS MA; TAN LB; KATZENSTEIN DA; MERIGAN TC
      BIOLOGICAL VARIATION AND QUALITY-CONTROL OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA QUANTITATION BY REVERSE-TRANSCRIPTASE POLYMERASECHAIN-REACTION

      Journal of clinical microbiology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/05/20 alle ore 01:57:32